Facebook
Twitter
Telegram
Report an ErrorBenitec Biopharma Balance Sheet 2011-2024 | BNTC
Annual Balance Sheet Benitec Biopharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-1.92 M | -3.25 M | - | -9.4 M | -15.7 M | -11.8 M | -13.4 M | -13.6 M | -16.7 M | -20.5 M | -28.6 M | - | - |
Long Term Debt |
284 K | 559 K | - | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
275 K | 252 K | 213 K | 192 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 213 K | - | 35.3 K | 26.9 K | 13.4 K | - | - | - | - | - |
Total Current Liabilities |
3.98 M | 2.53 M | 1.37 M | 1.14 M | - | - | - | - | - | - | - | - | - |
Total Liabilities |
4.26 M | 3.09 M | 1.37 M | 1.35 M | 2.64 M | 1.91 M | 891 K | 786 K | 1.26 M | 1.55 M | 872 K | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-168 M | -148 M | -130 M | -117 M | -98.9 M | -108 M | -104 M | -98.1 M | -82.7 M | -101 M | -87.9 M | - | - |
Total Assets |
4.46 M | 5.97 M | 21.4 M | 11.6 M | 19.2 M | 15.7 M | 17.4 M | 14.9 M | 19.6 M | 24 M | 31.5 M | - | - |
Cash and Cash Equivalents |
2.48 M | 4.06 M | 19.8 M | 9.8 M | 15.7 M | - | - | - | - | - | - | - | - |
Book Value |
202 K | 2.88 M | 20 M | 10.2 M | 16.6 M | 13.8 M | 16.5 M | 14.1 M | 18.3 M | 22.5 M | 30.6 M | - | - |
Total Shareholders Equity |
202 K | 2.88 M | 20 M | 10.2 M | 16.6 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Benitec Biopharma
| 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
62 K | 137 K | 211 K | 284 K | 354 K | 422 K | 491 K | 559 K | 635 K | 698 K | 760 K | - | - | 108 K | 161 K | 213 K | 213 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
3.5 M | 5.88 M | 4.74 M | 4.26 M | 3.51 M | 2.91 M | 3.5 M | 3.09 M | 2.54 M | 3.18 M | 2.36 M | 1.37 M | 1.37 M | 887 K | 1.18 M | 1.35 M | 1.35 M | - | - | 2.64 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-185 M | -181 M | -174 M | -168 M | -163 M | -159 M | -153 M | -148 M | -143 M | -140 M | -135 M | -130 M | -130 M | -122 M | -119 M | -117 M | -117 M | - | - | -109 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
15 M | 21.4 M | 27.1 M | 4.46 M | 8.22 M | 11.9 M | 18.1 M | 5.97 M | 10.1 M | 14 M | 17.8 M | 21.4 M | 21.4 M | 15.5 M | 8.92 M | 11.6 M | 11.6 M | - | - | 19.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
14.1 M | 20.4 M | 25.9 M | 2.49 M | 6.56 M | 10.6 M | 16.5 M | 4.06 M | 8.63 M | 12.3 M | 15.7 M | 19.8 M | 19.8 M | 14 M | 7.45 M | 14 M | 7.45 M | 13.8 M | 16.6 M | 15.7 M | - | - | - | 11.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
11.5 M | 15.5 M | 22.3 M | 202 K | 4.71 M | 8.99 M | 14.6 M | 2.88 M | 7.52 M | 10.8 M | 15.5 M | 20 M | 20 M | 14.6 M | 7.74 M | 10.2 M | 10.2 M | - | - | 16.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
11.5 M | 15.5 M | 22.3 M | 202 K | 4.71 M | 8.99 M | 14.6 M | 2.88 M | 7.52 M | 10.8 M | 15.5 M | 20 M | 15.5 M | 14.6 M | 14.6 M | 14.6 M | 7.74 M | 15.3 M | 17 M | 16.6 M | - | - | - | 13.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency